Review on PDGFRA, with data on DNA/RNA, on the protein encoded and where the gene is implicated.
Protein

Description
Size: 1089 amino acids; molecular weight: 122670 Da. Subunit: Interacts with dimeric PDGFA, PDGFB and/or PDGFC; heterodimers with PDGFRB. Present in an inactive conformation as a monomer in the absence of bound ligand.
Expression
PDGFR expression is characteristic of various mesodermal derivatives; specially expressed in the urinary tracts and in male and female genitals.
Localisation
Subcellular location: cell membrane.
Function
Member of the type III class of tyrosine kinase receptors which also includes c-KIT, FLT3 and the macrophage-colony-stimulating factor receptor; characterized by five immunoglobuline-like extracellular domains; a single-spanning transmembrane domain and an intracellular split kinase domain, connected by a flexible polypeptide insert; structurally homologous to c-KIT. PDGFA has transmembrane receptor protein tyrosine kinase activity and acts as a cell-surface receptor for members of the platelet-derived growth factor family: PDGFA, PDGFB and PDGFC, which are mitogens for fibroblasts and cells of mesenchymal origin origin. It plays an essential role in the regulation of many biological processes including cell proliferation, survival, differentiation and cell migration. Plays an important role in embryonic development, in the adult control tissue homeostasis in various organs including kidney, epidydimis, lung and pancreas; required for normal development of intestinal villi in the gastrointestinal tract, plays a role in platelet activation, wound healing and angiogenesis (Demoulin et al., 2012; Heldin et al., 2013) . Regulation: Function as homo-and/or heterodimers depending on the cell type; activated by ligandinduced dimerization and autophosphorylation on specific tyrosine residues upon binding. Activation of the intracellular kinase activity of the receptor leads to creation of docking sites for signal transduction molecules. Subsequent phosphorylation of its substrates initiates a variety of signal transduction cascades that promotes cell proliferation, survival and migration through the PI3K-AKT-mTOR and RAS-MAPK pathways as well as promotes activation of STAT family members (JAK/STAT) (Demoulin et al., 2012) .
Mutations
Note Mutations in the PDGFRA gene contribute to the pathophysiology of various diseases such as atherosclerosis, abnormalities of the tubal neural development and fibrotic diseases. In cancer, activating point mutations, gene amplifications and chromosomal rearrangements including gene fusions and chromosomal deletions have been found in certain malignancies. These include hematological malignancies such as acute myeloid leukemia, atypical chronic myelogenous leukemia, chronic myelomonocytic leukemia, eosinophilic disorders and mastocytosis (Gotlib et al., 2008) .
PDGFRA mutations also have been described in somatic and familial gastrointestinal stromal tumors, synovial sarcomas, glioblastoma, malignant peripheral nerve sheath tumors, melanoma and a in a variety of other cancers (Chompret et al., 2004; Heinrich et al., 2003) .
Implicated in
Gastrointestinal stromal tumor (GIST)
Note Activating mutations of PDGFRA are found in 5-8% of patients with gastrointestinal stromal tumors (GISTs) but their frequency increases to 30% to 40% in gastric GISTs lacking KIT mutations (Corless et al., 2005; Lasota et al., 2008) . The majority of these mutations are "substitution missense", that can arise by various mechanisms (Figure 1 ). These include mutation hot spots in exon 18 of the PDGFRA gene such as the Asp-to-Val substitution at codon 842 (D842V) encoding the activation loop. Other activating mutations are less frequent such as mutations in exons 12 encoding the juxtamembrane domain and in exon 14 encoding the tyrosine kinase 1 domain of PDGFRA (Chompret et al., 2004; Heinrich et al., 2003) . PDGFRA mutations except for D842V in exon 18 are sensitive to imatinib inhibition. However, despite initial clinical responses to tyrosine kinase inhibitors (imatinib, nilotinib, sorafenib and sunatinib), the majority of these patient develops resistance to the drug limiting the long-term benefit of tyrosine kinase inhibitors in this group of patients (Gramza et al., 2009; Pierotti et al., 2011) . Figure 2 . The structure and mechanism of activation of PDGFRA fusions in hematological disorders. In the fusion oncogene, the partner gene always replaces the 5 part of exon 12 of PDGFRA creating an in frame fusion. As the 5 part of exon 12 of PDGFRA containing the inhibitory domain is truncated, its expression is controlled by the partner gene promoter resulting in constitutive activation of the PDGFRA kinase domain. NH2: N-terminal site; COOH: C-terminal site; TM: transmembrane domain; JM: juxtamembrane domain. Adopted and modified from Cools et al., 2003 and Gotlib et al., 2008) .
The D842V mutation results in an amino acid substitution at position 842 in PDGFRA, from an aspartic acid (D) to a valine (V). This mutation occurs within the TK2 domain (Figure 1 ). PDGFRA D842V mutation has been found in a distinct subset of GIST, typically from the stomach. The D842V mutation is known to be associated with tyrosine kinase inhibitor resistance.
Hematologic disorders with primary eosinophilia
Note Several chromosomal rearrangements generating fusion genes causing PDGFRA activation have been described in a variety of uncommon hematologic disorders that are often accompanied with a related condition called hypereosinophilic syndrome. These rearrangements activate PDGFRA by fusion to various partner genes: STRN (2p24) in the t(2;4)(p22;q12), FIP1L1 (interstitial 4q12 deletion), CDK5RAP2 (9q33) in the ins(9;4)(q33;q12q25), KIF5B (10p11) in the t(4;10)(q12;p11), ETV6 (12p13) in the t(4;12)(q12;p13), and BCR (22q11) in the t(4;22)(q12;q11). In each of these rearrangements, the breakpoints in PDGFRA partner genes are variable, but the breakpoints in PDGFRA invariably involve exon 12 encoding a portion of the juxtamembrane domain with autoinhibitory function (Baxter et al., 2002; Gotlib et al., 2008) ; the disruption of which activates the fusion protein (Figure 2) . The most investigated of these fusion genes is FIP1L1-PDGFRA that arise as a result of a cryptic interstitial deletion on chromosome 4q12. FIP1L1-PDGFRA fusion protein is involved in the pathogenesis of uncommon hematologic disorders with primary eosinophilia like chronic eosinophilic leukemia (CEL) hyperseosinophilic syndrome (HES) and systemic mastocytosis (SM). Similar to other fusion tyrosine kinases, FIP1L1-PDGFRA is a constitutively active tyrosine kinase that was shown to be sensitive to kinase inhibitors (Cools et al., 2003; Jain et al., 2013) .
Lung adenocarcinoma
Cytogenetics A t(4;12)(q12;q12) was found in a case of lung adenocarcinoma (Seo et al., 2012 
